People · Operator

Radu Cautis

Named in public records as an officer, director or promoter · active 2017–2025 · Medical Devices, Other Health Care

2
Companies
6
Filings
$90.9M
Combined raised · real
Serial
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Zenflow, Inc.Medical DevicesSeries B$75.3M$116.7M2017
Centese, Inc.Other Health CareSeries B$15.6M$2.7M2023
Operator network

Radu Cautis at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Robert Weisskoff · 12 companies · 1 sharedRobert WeisskoffAndrew Cleeland · 5 companies · 1 sharedAndrew CleelandBryan Kim · 4 companies · 1 sharedBryan KimJohn Beck · 3 companies · 1 sharedJohn BeckSusan Stimson · 2 companies · 1 sharedSusan StimsonBlayne Roeder · 1 companies · 1 sharedBlayne RoederNicholas Damiano · 1 companies · 1 sharedNicholas DamianoNick Damiano · 1 companies · 1 sharedNick DamianoShreya Mehta · 1 companies · 1 sharedShreya MehtaDaniel Burnett · 11 companies · 1 sharedDaniel BurnettAlan Chesler · 5 companies · 1 sharedAlan CheslerEvan Luxon · 3 companies · 1 sharedEvan LuxonDan Burnett · 2 companies · 1 sharedDan BurnettDeepak Gangahar · 2 companies · 1 sharedDeepak GangaharZenflow, Inc. · $75.3M raisedZenflow, Inc.Centese, Inc. · $15.6M raisedCentese, Inc.Radu CautisRC
Radu Cautis Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Radu Cautis on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Robert Weisskoff112
Daniel Burnett111
Alan Chesler15
Andrew Cleeland15
Bryan Kim14
Evan Luxon13
John Beck13
Dan Burnett12
Deepak Gangahar12
Susan Stimson12
Blayne Roeder11
Shreya Mehta11
Nick Damiano11
Nicholas Damiano11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.